Results 11 to 20 of about 14,897 (305)

Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy

ESC Heart Failure, 2023
Aims Peripartum cardiomyopathy (PPCM) is a rare heart disease, occurring in previously heart‐healthy women during the last month of pregnancy or the first months after delivery due to left ventricular (LV) systolic dysfunction.
Tobias J. Pfeffer, Julia H. Mueller, Lea Haebel, Sergej Erschow, Kuebra C. Yalman, Steven R. Talbot, Tobias Koenig, Dominik Berliner, Carolin Zwadlo, Michaela Scherr, Denise Hilfiker‐Kleiner, Johann Bauersachs, Melanie Ricke‐Hoch   +12 more
doaj   +2 more sources

Is Cabergoline Safe and Effective for Postpartum Lactation Inhibition? A Systematic Review

International Journal of Women's Health, 2020
Yang Yang,1 Isabelle Boucoiran,2 Karen J Tulloch,3 Vanessa Poliquin4 1University of Manitoba, Winnipeg, MB, Canada; 2Department of Obstetrics & Gynecology, Université de Montréal, Montreal, QC, Canada; 3BC Women’s Hospital ...
Yang Y, Boucoiran I, Tulloch KJ, Poliquin V   +3 more
doaj   +2 more sources

Cabergoline in Parkinson's disease [PDF]

Neurology, 1995
Contains fulltext : 21612___.PDF (Publisher’s version ) (Open Access)
Horstink, M.W.I.M., Berger, H.J.C., Vlasakker, C.J.W. van de   +2 more
  +10 more sources

Antioxidant and neuroprotective effects of cabergoline

Japanese Journal of Pharmacology, 2000
Kenichi Tanaka, Ikuko Miyazaki, Masato Asanuma, Naoko Fujita, Norio Oaawa   +4 more
openalex   +3 more sources

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease

Frontiers in Endocrinology, 2023
Objective This study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing’s disease (CD). Study design This
R. Feelders, M. Fleseriu, P. Kadıoğlu, M. Bex, Deyanira González-Devia, C. Boguszewski, Dilek Gogas Yavuz, Heather Patino, A. Pedroncelli, R. Maamari, Arghya Chattopadhyay, B. Biller, R. Pivonello   +12 more
semanticscholar   +1 more source

Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study

Nutrients, 2023
Both hyperprolactinemia and vitamin D deficiency appear to be associated with increased cardiometabolic risk. This study aimed to determine whether vitamin D status influences the cardiometabolic effects of cabergoline.
R. Krysiak, M. Basiak, G. Machnik, W. Szkróbka, B. Okopień   +4 more
semanticscholar   +1 more source

Effects of combined metformin and cabergoline versus metformin alone on ovarian and hormonal activities in Iraqi patients with PCOS and hyperprolactinemia: a randomized clinical trial

Journal of Medicine and Life, 2023
Polycystic ovary syndrome (PCOS) is one of the most prevalent metabolic diseases during female reproductive life, often associated with insulin resistance and hyperprolactinemia. The efficacy of metformin and cabergoline for managing PCOS remains debated
Inas Naser Hamad, S. A. Kadhim, Hayder Adnan Fawzi, Shoroq Mohammed Al-Temimi, Bassim I Mohammad, Asma A Swadi   +5 more
semanticscholar   +1 more source

Pharmacological effects of cabergoline against parkinsonism.

Folia Pharmacologica Japonica, 2001
The pharmacological effects of cabergoline, a novel ergot alkaloid, against parkinsonism were assessed by comparing its effects with those of bromocriptine and pergolide. The affinities of cabergoline and pergolide for the D2 receptor were about the same, about 7 times stronger than that of bromocriptine.
Kiyoshi Ichikawa, Masami Kojima
openalex   +4 more sources

A Practical Synthesis of Cabergoline [PDF]

The Journal of Organic Chemistry, 2002
Cabergoline is an N-acylurea derived from 9,10-dihydrolysergic acid, which is a potent prolactin inhibitor. It is marketed by Pharmacia as Dostinex for the treatment of hyperprolactinemia and is currently under active development for the treatment of a variety of CNS disorders.
Kevin E. Henegar, Peter G. M. Wuts, Andrew M. Anderson, Scott W. Ashford   +3 more
openaire   +4 more sources

Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study

The Cardiology, 2022
Introduction: Hypoprolactinemia, which is usually a consequence of treatment with inadequate high doses of dopaminergic agents, is a poorly understood clinical condition. The aim of the current study was to investigate whether the cardiometabolic effects
R. Krysiak, K. Kowalcze, B. Okopień
semanticscholar   +1 more source